Search

Your search keyword '"Akashi, Yusaku"' showing total 163 results
Start Over Author "Akashi, Yusaku"
163 results on '"Akashi, Yusaku"'

18. Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single‐plex testing: WJOG13620L

Author

Uemura, Takehiro, primary, Kenmotsu, Hirotsugu, additional, Hazama, Daisuke, additional, Teraoka, Shunsuke, additional, Kobe, Hiroshi, additional, Azuma, Koichi, additional, Yamaguchi, Teppei, additional, Masuda, Takeshi, additional, Yokoyama, Toshihide, additional, Otsubo, Kohei, additional, Haratani, Koji, additional, Hayakawa, Daisuke, additional, Oki, Masahide, additional, Takemoto, Shinnosuke, additional, Ozaki, Tomohiro, additional, Akashi, Yusaku, additional, Hata, Akito, additional, Hashimoto, Hiroya, additional, Yamamoto, Nobuyuki, additional, and Nakagawa, Kazuhiko, additional

Published
2023
Full Text
View/download PDF

19. Development of a mobile laboratory system in hydrogen fuel cell buses and evaluation of the performance for COVID-19

Author

Okude, Miho, primary, Suzuki, Kenji, additional, Naito, Asami, additional, Ebashi, Akio, additional, Kusama, Tomoka, additional, Kiyotaki, Junichi, additional, Akashi, Yusaku, additional, Kiyasu, Yoshihiko, additional, Kurihara, Yoko, additional, Notake, Shigeyuki, additional, Takanashi, Masaki, additional, Setoyama, Tomokazu, additional, Kawakami, Yasushi, additional, and Suzuki, Hiromichi, additional

Published
2023
Full Text
View/download PDF

23. Analytical performance of rapid antigen tests for the detection of SARS-CoV-2 during widespread circulation of the Omicron variant

Author

Suzuki, Hiromichi, primary, Akashi, Yusaku, additional, Kato, Daisuke, additional, Takeuchi, Yuto, additional, Kiyasu, Yoshihiko, additional, Terada, Norihiko, additional, Kurihara, Yoko, additional, Kuwahara, Miwa, additional, Muramatsu, Shino, additional, Ueda, Atsuo, additional, Notake, Shigeyuki, additional, and Nakamura, Koji, additional

Published
2022
Full Text
View/download PDF

24. Clinical Performance of the cobas Liat SARS-CoV-2 & Influenza AB for the Detection of SARS-CoV-2 in Nasal Samples

Author

Akashi, Yusaku, primary, Horie, Michiko, additional, Kiyotaki, Junichi, additional, Takeuchi, Yuto, additional, Togashi, Kenichi, additional, Adachi, Yuki, additional, Ueda, Atsuo, additional, Notake, Shigeyuki, additional, Nakamura, Koji, additional, Terada, Norihiko, additional, Kurihara, Yoko, additional, Kiyasu, Yoshihiko, additional, and Suzuki, Hiromichi, additional

Published
2022
Full Text
View/download PDF

25. Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer

Author

Suzuki, Shinichiro, primary, Haratani, Koji, additional, Hayashi, Hidetoshi, additional, Chiba, Yasutaka, additional, Tanizaki, Junko, additional, Kato, Ryoji, additional, Mitani, Seiichiro, additional, Kawanaka, Yusuke, additional, Kurosaki, Takashi, additional, Hasegawa, Yoshikazu, additional, Okabe, Takafumi, additional, Tanaka, Kaoru, additional, Akashi, Yusaku, additional, Ozaki, Tomohiro, additional, Nishio, Kazuto, additional, Ito, Akihiko, additional, and Nakagawa, Kazuhiko, additional

Published
2022
Full Text
View/download PDF

26. Diagnostic performance of microscopic stool examination in Campylobacter infection performed by different medical specialties.

Author

Hirose, Yumi, Akashi, Yusaku, Sun, Yu, Notake, Shigeyuki, Ueda, Atsuo, Kato, Daisuke, Muramatsu, Shino, Ishikawa, Hiroichi, and Suzuki, Hiromichi

Subjects
CAMPYLOBACTER infections, MEDICAL specialties & specialists, MEDICAL technologists, ANTIGEN analysis, GRAM'S stain
Abstract

Background: Microscopic examination of stool samples can contribute to the early diagnosis of Campylobacter gastroenteritis. However, it is unclear whether the diagnostic performance is reliable when performed by physicians. Methods: This prospective study included fresh stool samples collected from patients with gastroenteritis between August 2018 and March 2020. The samples were used for microscopic examination through Gram staining. Two physicians, a clinical laboratory technician, and microbiologists performed the examinations. In addition, antigen tests (QuickNavi‐Campylobacter; Denka Co., Ltd.) were evaluated for the samples collected between May 2019 and March 2020. Infection with Campylobacter spp. was confirmed when stool cultures or polymerase chain reaction tests provided positive results. Results: Microscopic examination was performed on 205 samples, of which 46 (22.4%) were positive for Campylobacter spp. For the microscopic examination, the sensitivity and specificity were 53.5% and 98.1% for physician A, 46.7% and 96.2% for physician B, 63.0% and 100% for the clinical laboratory technician, and 67.4% and 100% for microbiologists, respectively. The antigen testing was evaluated in 131 of the 205 samples and showed a sensitivity of 93.3% and specificity of 99.0%. Conclusions: Microscopic examination of the stool samples showed high specificity. The sensitivity when the examinations were performed by the physicians was insufficient. The rapid antigen tests can reliably detect Campylobacter spp. in stool samples. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Clinical Evaluation of a Combo Rapid Antigen Test QuickNavi-Flu+COVID19 Ag for Simultaneous Detection of SARS-CoV-2 and Influenza Viruses

Author

Takeuchi, Yuto, primary, Akashi, Yusaku, additional, Kiyasu, Yoshihiko, additional, Terada, Norihiko, additional, Kurihara, Yoko, additional, Kato, Daisuke, additional, Miyazawa, Takashi, additional, Muramatsu, Shino, additional, Shinohara, Yuki, additional, Ueda, Atsuo, additional, Notake, Shigeyuki, additional, Nakamura, Koji, additional, and Suzuki, Hiromichi, additional

Published
2021
Full Text
View/download PDF

31. Clinical Evaluation of the Novel Rapid Nucleic Acid Amplification Point-of-Care Test (Smart Gene SARS-CoV-2) in the analysis of Nasopharyngeal and Anterior Nasal samples

Author

Kiyasu, Yoshihiko, primary, Owaku, Masato, additional, Akashi, Yusaku, additional, Takeuchi, Yuto, additional, Narahara, Kenji, additional, Mori, Sunao, additional, Nagano, Takashi, additional, Notake, Shigeyuki, additional, Ueda, Atsuo, additional, Nakamura, Koji, additional, Ishikawa, Hiroichi, additional, and Suzuki, Hiromichi, additional

Published
2021
Full Text
View/download PDF

33. Diagnostic performance of a novel digital immunoassay (RapidTesta SARS-CoV-2): a prospective observational study with 1,127 nasopharyngeal samples

Author

Suzuki, Hiromichi, primary, Akashi, Yusaku, additional, Ueda, Atsuo, additional, Kiyasu, Yoshihiko, additional, Takeuchi, Yuto, additional, Maehara, Yuta, additional, Ochiai, Yasushi, additional, Okuyama, Shinya, additional, Notake, Shigeyuki, additional, Nakamura, Koji, additional, and Ishikawa, Hiroichi, additional

Published
2021
Full Text
View/download PDF

37. The evaluation of a novel digital immunochromatographic assay with silver amplification to detect SARS-CoV-2

Author

Kurihara, Yoko, primary, Kiyasu, Yoshihiko, additional, Akashi, Yusaku, additional, Takeuchi, Yuto, additional, Narahara, Kenji, additional, Mori, Sunao, additional, Takeshige, Tomonori, additional, Notake, Shigeyuki, additional, Ueda, Atsuo, additional, Nakamura, Koji, additional, Ishikawa, Hiroichi, additional, and Suzuki, Hiromichi, additional

Published
2021
Full Text
View/download PDF

48. A Prospective Evaluation of the Analytical Performance of GENECUBE® HQ SARS-CoV-2 and GENECUBE® FLU A/B.

Author

Kiyasu, Yoshihiko, Akashi, Yusaku, Sugiyama, Akio, Takeuchi, Yuto, Notake, Shigeyuki, Naito, Asami, Nakamura, Koji, Ishikawa, Hiroichi, and Suzuki, Hiromichi

Subjects
*SARS-CoV-2, *COVID-19, *MIDDLE East respiratory syndrome, *INFLUENZA, *POLYMERASE chain reaction
Abstract

Background: Molecular tests are the mainstay of detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, their accessibility can be limited by the long examination time and inability to evaluate multiple samples at once. Objective: This study evaluated the analytical performance of the newly developed rapid molecular assays GENECUBE® HQ SARS-CoV-2 and GENECUBE® FLU A/B. Method: This prospective study was conducted between 14 December 2020 and 9 January 2021 at a polymerase chain reaction (PCR) center. Samples were collected from the nasopharynx with flocked swabs. Molecular tests were performed with the GENECUBE® system and reference reverse transcription (RT)-PCR, and the results of the two assays were compared. Result: Among 1065 samples, 81 (7.6%) were positive for SARS-CoV-2 on the reference RT-PCR. Three showed discordance between GENECUBE® HQ SARS-CoV-2 and the reference RT-PCR; the total, positive, and negative samples of concordance for the two assays were 99.7%, 100%, and 99.7%, respectively. All discordant cases were positive with GENECUBE® HQ SARS-CoV-2 and negative with the reference RT-PCR. SARS-CoV-2 was detected in all three samples using another molecular assay for SARS-CoV-2. For GENECUBE® FLU A/B, the total, positive, and negative samples of concordance for the two assays were 99.5%, 100%, and 99.1%. Conclusion: The GENECUBE® HQ SARS-CoV-2 and GENECUBE® FLU A/B demonstrated sufficient analytical performance to detect SARS-CoV-2 and influenza virus A/B. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

49. Evaluation of performance of the GENECUBE assay for rapid molecular identification of Staphylococcus aureus and methicillin resistance in positive blood culture medium

Author

Hida, Yukio, primary, Uemura, Keiichi, additional, Sugimoto, Hiroyasu, additional, Kawashima, Yosuke, additional, Koyanagi, Norito, additional, Notake, Shigeyuki, additional, Akashi, Yusaku, additional, Sakaguchi, Shohei, additional, Kimura, Hideki, additional, and Suzuki, Hiromichi, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results